Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 38 · MACD below its signal
None of the 29 investors followed here reported a position in CANC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CANC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.0 | 5.7 | -2.9 | 2.2 | 1.6 | 8.3 | -1.6 | 6.8 | -3.1 | -5.4 | +14.4% | ||
| 2025 | 5.7 | -0.2 | -6.1 | 3.7 | -2.8 | 1.8 | 4.8 | 2.9 | 7.7 | 7.9 | 15.4 | -2.9 | +42.8% |
| 2024 | -0.9 | 7.9 | -0.3 | -5.5 | 0.7 | 0.9 | 8.9 | 1.7 | -4.9 | -2.8 | 0.7 | -12.6 | −7.9% |
| 2023 | -7.6 | -5.0 | 9.2 | 9.9 | +5.3% |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.